MFDS — authorised 5 May 2017
- Marketing authorisation holder: MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC
- Status: likely_approved
🇰🇷 Radicava in South Korea
MFDS authorised Radicava on 5 May 2017
Marketing authorisation
Radicava in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in South Korea
Frequently asked questions
Is Radicava approved in South Korea?
Yes. MFDS authorised it on 5 May 2017.
Who is the marketing authorisation holder for Radicava in South Korea?
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC holds the South Korean marketing authorisation.